December 12, 2025

FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis – NeurologyLive

December 12, 2025

FDA Approves Amgen’s UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), Expanding Treatment Options for Patients Living with Autoimmune Neuromuscular Disease – Muscular Dystrophy Association

December 12, 2025

FDA Approves Inebilizumab for Generalized Myasthenia Gravis – American Journal of Managed Care

December 12, 2025

FDA Approves Amgen’s Uplizna for Generalized Myasthenia Gravis With Positive AChR or MuSK Antibodies – Pharmaceutical Executive

December 11, 2025

FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS – PR Newswire